porozendoОстеопороз и остеопатииOsteoporosis and Bone Diseases2072-26802311-0716Endocrinology Research Centre10.14341/osteo2006323-30porozendo-4082Research ArticleСтатьиArticlesИбандронат (Бонвива) - новые возможности в лечении остеонороза: повышение приверженности к терапии - оптимизация исходов леченияIbandronat (Bonviva) - novye vozmozhnosti v lechenii osteonoroza: povyshenie priverzhennosti k terapii - optimizatsiya iskhodov lecheniyaBelayaZh E-RozhinskayaL Ya-Mel'nichenkoG A-20061512200693№3 (2006)2330Copyright © Belaya Z.E., Rozhinskaya L.Y., Mel'nichenko G.A., 20062006Belaya Z.E., Rozhinskaya L.Y., Mel'nichenko G.A.Belaya Z.E., Rozhinskaya L.Y., Mel'nichenko G.A.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.osteo-endojournals.ru/jour/article/view/4082ReferencesЕвстигнеева Л.П., Лесняк О.М., Пивень А.И. Эпидемиология остеопоротических переломов позвоночника по данным рентгено- морфометрического анализа среди популяциионной выборки жителей г. Екатеринбурга 50 лет и старше. // Остеопороз и остеопатии, 2001; №2:2-6Евстигнеева Л.П., Лесняк О.М., Пивень А.И. Эпидемиология остеопоротических переломов позвоночника по данным рентгено- морфометрического анализа среди популяциионной выборки жителей г. Екатеринбурга 50 лет и старше. // Остеопороз и остеопатии, 2001; №2:2-6Ершова О.Б., Семенова О.В., Дегтярев А.А. Результаты проспективного изучения исходов переломов проксимального отдела бедра. // Остеопороз и остеопатии, 2000; № 1: 9-10.Ершова О.Б., Семенова О.В., Дегтярев А.А. Результаты проспективного изучения исходов переломов проксимального отдела бедра. // Остеопороз и остеопатии, 2000; № 1: 9-10.Лесняк О.М. Фармакоэкономика средств профилактики и лечения остеопороза. // В кн. «Руководство по остеопорозу», Москва, «Бином» 2003: 469--481.Лесняк О.М. Фармакоэкономика средств профилактики и лечения остеопороза. // В кн. «Руководство по остеопорозу», Москва, «Бином» 2003: 469--481.Меньшикова Л.В., Храмцова Н.А., Ершова О.Б. и др. Ближайшие и отдаленные исходы переломов проксимального отдела бедра у лиц пожилого возраста и их медико-социальные последствия (по данным многоцентрового исследования). // Остеопороз и остеопатии, 2002; № 1: 8-11.Меньшикова Л.В., Храмцова Н.А., Ершова О.Б. и др. Ближайшие и отдаленные исходы переломов проксимального отдела бедра у лиц пожилого возраста и их медико-социальные последствия (по данным многоцентрового исследования). // Остеопороз и остеопатии, 2002; № 1: 8-11.Bartl R., Goette S., Hadji P., Hammerschmidt Т.: Persistence and compliance with daily- and weekly-administered bisphosphonates in German women with osteoporosis ECCEO, 2005 Poster (P I95)Bartl R., Goette S., Hadji P., Hammerschmidt Т.: Persistence and compliance with daily- and weekly-administered bisphosphonates in German women with osteoporosis ECCEO, 2005 Poster (P I95)Baus F., Lalla S., Endele R., Hothorn L.H.: The effects of treatment with ibandronate on bone mass, architecture, biomechanical properties and bone concentration of ibandronate in ovariectomized aged rats. // J. Rheumatology, 2002, Vol. 29, pp. 2200-2208Baus F., Lalla S., Endele R., Hothorn L.H.: The effects of treatment with ibandronate on bone mass, architecture, biomechanical properties and bone concentration of ibandronate in ovariectomized aged rats. // J. Rheumatology, 2002, Vol. 29, pp. 2200-2208Baus F., Wagner M., Hothorn L.H.: Total administered dose of ibandronate determines its effects on bone mass and architecture in ovariectomized aged rats. // J. Rheumatology, 2002b, Vol. 29, pp. 990-998Baus F., Wagner M., Hothorn L.H.: Total administered dose of ibandronate determines its effects on bone mass and architecture in ovariectomized aged rats. // J. Rheumatology, 2002b, Vol. 29, pp. 990-998Bauss F., Russell R.G.G.: Ibandronate in osteoporosis: preclinical data and rationale for intermittent dosing. // Osteoporosis International, 2003, Vol. 15, pp. 423-433Bauss F., Russell R.G.G.: Ibandronate in osteoporosis: preclinical data and rationale for intermittent dosing. // Osteoporosis International, 2003, Vol. 15, pp. 423-433Black D.M., Cummings S.R., Karpf D.B., et al.: Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture intervention trial research group // Lancet, 1996, Vol. 348, pp. 1535-1541 5.Black D.M., Cummings S.R., Karpf D.B., et al.: Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture intervention trial research group // Lancet, 1996, Vol. 348, pp. 1535-1541 5.Body J.J., Diel I.J., Lichinister M.R., et al.: Ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastasis (MF4265 Study Group). // Annual Oncology, 2003, Vol. 14, pp. 1399-1405Body J.J., Diel I.J., Lichinister M.R., et al.: Ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastasis (MF4265 Study Group). // Annual Oncology, 2003, Vol. 14, pp. 1399-1405Body J.J.: Dosing regimens and main adverse events of bisphosphonates. // Seminars in Oncology, 2001, Vol. 28, (suppl 11), pp. 49-53Body J.J.: Dosing regimens and main adverse events of bisphosphonates. // Seminars in Oncology, 2001, Vol. 28, (suppl 11), pp. 49-53Bone H.G., Adami S., Rizzoli R., Favus M., Ross P.D., Santora A., Prahalada S., Daifotis A., Orloff J., Yates J.: Weekly administration ofBone H.G., Adami S., Rizzoli R., Favus M., Ross P.D., Santora A., Prahalada S., Daifotis A., Orloff J., Yates J.: Weekly administration ofBoonen S., Haentjens P., Vandenput L., Vanderschueren D.: Pre venting osteoporotic fractures with antiresorptive therapy: implications on microarchitectural changes. // J Internal Medicine, 2004, Vol. 255, pp. 1-12Boonen S., Haentjens P., Vandenput L., Vanderschueren D.: Pre venting osteoporotic fractures with antiresorptive therapy: implications on microarchitectural changes. // J Internal Medicine, 2004, Vol. 255, pp. 1-12Brown J.P., Kendler D.L., McClung M.R., Emkey R.D., Adachi J.D., Bolognese M.A., Li Z., Balske A., Lindsay R.: The efficacy and tolerability of risedronate once a week for the treatment of postmeno pausal osteoporosis. // Calcified Tissue International, 2002, Vol. 71, pp. 103-111Brown J.P., Kendler D.L., McClung M.R., Emkey R.D., Adachi J.D., Bolognese M.A., Li Z., Balske A., Lindsay R.: The efficacy and tolerability of risedronate once a week for the treatment of postmeno pausal osteoporosis. // Calcified Tissue International, 2002, Vol. 71, pp. 103-111Brumsen C., Papapoulos S.E., Lips P., Geelhoed-Duijvestijn P.H., Hamdy N.A., Landman J.O., McCloskey E.V., Netelenbos J.C., Pauwels E.K., Roos J.C., Valentijn R.M., Zwinderman A.H.: Daily oral pamidronate in women and men with osteoporosis: a 3-year randomized placebo-con trolled clinical trial with a 2-year open extension. // J. Bone Mineral Research, 2002, Vol. 17, pp. 1057-1064Brumsen C., Papapoulos S.E., Lips P., Geelhoed-Duijvestijn P.H., Hamdy N.A., Landman J.O., McCloskey E.V., Netelenbos J.C., Pauwels E.K., Roos J.C., Valentijn R.M., Zwinderman A.H.: Daily oral pamidronate in women and men with osteoporosis: a 3-year randomized placebo-con trolled clinical trial with a 2-year open extension. // J. Bone Mineral Research, 2002, Vol. 17, pp. 1057-1064Campion G., Melton L.J.: Hip fractures in the elderly: a worldwide projection., Osteoporosis International, 1992, Vol. 2, pp. 285-289Campion G., Melton L.J.: Hip fractures in the elderly: a worldwide projection., Osteoporosis International, 1992, Vol. 2, pp. 285-289Chaiamnuay S., Saag K.G.: Postmenopausal osteoporosis. What have we learned since the introduction of bisphosphonates. Reviews En docrine Metabolic Disorders, 2006 (Epub ahead of print)Chaiamnuay S., Saag K.G.: Postmenopausal osteoporosis. What have we learned since the introduction of bisphosphonates. Reviews En docrine Metabolic Disorders, 2006 (Epub ahead of print)Chesnut C.H., Skag A., Christiansen C., Recker R., Stakkestad J.A., Hoiseth A., Felsenberg D., Huss H., Gilbride J., Schimmer R.S., Delmas P.D.: Effects of Oral Ibandronate Administered Daily or Intermittenly on Fracture risk in postmenopausal osteoporosis. // J. Bone and Mineral Research, 2004, Vol. 19, pp. 1241-1249-1Chesnut C.H., Skag A., Christiansen C., Recker R., Stakkestad J.A., Hoiseth A., Felsenberg D., Huss H., Gilbride J., Schimmer R.S., Delmas P.D.: Effects of Oral Ibandronate Administered Daily or Intermittenly on Fracture risk in postmenopausal osteoporosis. // J. Bone and Mineral Research, 2004, Vol. 19, pp. 1241-1249-1Cooper A., Drake J., Brankin E. on behalf of the persistent in vestigators: Treatment persistence with once-monthly ibandronate and patient support vs. once-weekly alendronate results from the PERSIST study. // International J Clinical Practice, 2006, Vol. 60, pp. 896-905Cooper A., Drake J., Brankin E. on behalf of the persistent in vestigators: Treatment persistence with once-monthly ibandronate and patient support vs. once-weekly alendronate results from the PERSIST study. // International J Clinical Practice, 2006, Vol. 60, pp. 896-905Cooper C., Atkinson E.J., Jacobsen S.J., O'Fallon M., Melton L.J.: Population-based study of survival after osteoporotic fractures. // American J. Epidemiology, 1993, Vol. 137, pp. 1001-1005Cooper C., Atkinson E.J., Jacobsen S.J., O'Fallon M., Melton L.J.: Population-based study of survival after osteoporotic fractures. // American J. Epidemiology, 1993, Vol. 137, pp. 1001-1005Cooper C., Emkey R.D., McDonald R.H., Hawker G., Bianchi G., Wilson K., Schimmer R.C.: Efficacy and safety of oral weekly ibandro nate in the treatment of postmenopausal osteoporosis. // J. Clinical Endo crinology Metabolism, 2003, Vol. 88, pp. 4609-4615Cooper C., Emkey R.D., McDonald R.H., Hawker G., Bianchi G., Wilson K., Schimmer R.C.: Efficacy and safety of oral weekly ibandro nate in the treatment of postmenopausal osteoporosis. // J. Clinical Endo crinology Metabolism, 2003, Vol. 88, pp. 4609-4615Cramer J.A., Silverman S.: Persistence with bisphosphonate treatment for osteoporosis: finding the root of the problem. // American J. Medicine, 2006, Vol. 119, (suppl 1) S12-17Cramer J.A., Silverman S.: Persistence with bisphosphonate treatment for osteoporosis: finding the root of the problem. // American J. Medicine, 2006, Vol. 119, (suppl 1) S12-17Gumming R.G., Nevitt M.C., Cummings S.R.: Epidemiology of hip fractures. // J. Epidemiology Review, 1997, Vol. 19, pp. 244-257Gumming R.G., Nevitt M.C., Cummings S.R.: Epidemiology of hip fractures. // J. Epidemiology Review, 1997, Vol. 19, pp. 244-257Cummings S.R., Black D.M., Thompson D.E., Applegate W.B., Barrett-Connor E., Musliner Т.А., Palermo L., Prineas R., Rubin S.M., Scott J.C.,Cummings S.R., Black D.M., Thompson D.E., Applegate W.B., Barrett-Connor E., Musliner Т.А., Palermo L., Prineas R., Rubin S.M., Scott J.C.,Vogt T., Wallace R., Yates A.J., LaCroix A.Z.: Effect of alendronate on risk of fracture in women with low bone density but without vertebral frac tures: results from the Fracture Intervention Trial. // J American Medical Association, 1998, Vol. 280 (24), pp. 2077-2082 6Vogt T., Wallace R., Yates A.J., LaCroix A.Z.: Effect of alendronate on risk of fracture in women with low bone density but without vertebral frac tures: results from the Fracture Intervention Trial. // J American Medical Association, 1998, Vol. 280 (24), pp. 2077-2082 6Delmas P., Recker R., Stakkestad J.A., et al.: Oral ibandronate significantly reduces fracture risk in postmenopausal osteoporosis when administrated daily or with a unique drug-free interval: results from a pivotal phase HI study (abstract) // Osteoporosis International, 2002, Vol. 13, (suppl 1), S15.Delmas P., Recker R., Stakkestad J.A., et al.: Oral ibandronate significantly reduces fracture risk in postmenopausal osteoporosis when administrated daily or with a unique drug-free interval: results from a pivotal phase HI study (abstract) // Osteoporosis International, 2002, Vol. 13, (suppl 1), S15.Eastell R., Reid D.M., Comston J., Cooper C., Fogelman I., Francis R.M., Hay S.M., Hosking D.J., Purdie D.W., Ralston S.H., Reeve J., RussellR.G., Stevenson J.C.: Secondary prevention of osteoporosis when should a non-vertebral fracture be a trigger for action? // Monthly J Association Physicians, 2001, Vol. 94, pp. 575-597Eastell R., Reid D.M., Comston J., Cooper C., Fogelman I., Francis R.M., Hay S.M., Hosking D.J., Purdie D.W., Ralston S.H., Reeve J., RussellR.G., Stevenson J.C.: Secondary prevention of osteoporosis when should a non-vertebral fracture be a trigger for action? // Monthly J Association Physicians, 2001, Vol. 94, pp. 575-597Emkey M., Lewiecki E.M., Burdeska A., Mairon N., Rowell L., Eisman J.A.: Two-year efficacy and tolerability of intermittent intrave nous ibandronate injections in postmenopausal osteoporosis: the DIVA study, 2005 3Emkey M., Lewiecki E.M., Burdeska A., Mairon N., Rowell L., Eisman J.A.: Two-year efficacy and tolerability of intermittent intrave nous ibandronate injections in postmenopausal osteoporosis: the DIVA study, 2005 3Emkey R., Koltun W., Beusterien K., Seidman L., Kivitz A., Devas V., Masanauskaite D.: Patient preference for once-monthly ibandronate versus once-weekly alendronate in a randomized open-label, cross-over trial: the Bonviva Alendronate Trial in Osteoporosis (BALTO). // Current Medical Research Opinion, 2005, Vol. 21, pp. 1895-1903Emkey R., Koltun W., Beusterien K., Seidman L., Kivitz A., Devas V., Masanauskaite D.: Patient preference for once-monthly ibandronate versus once-weekly alendronate in a randomized open-label, cross-over trial: the Bonviva Alendronate Trial in Osteoporosis (BALTO). // Current Medical Research Opinion, 2005, Vol. 21, pp. 1895-1903Emkey R.D., Ettinger M.: Improving compliance and persistence with bisphosphonate therapy for osteoporosis. // American J Medicine, 2006, Vol. 119 (suppl 1): S18-24Emkey R.D., Ettinger M.: Improving compliance and persistence with bisphosphonate therapy for osteoporosis. // American J Medicine, 2006, Vol. 119 (suppl 1): S18-24Emkey R.D., Ettinger M.: Improving compliance and persistence with bisphosphonate therapy for osteoporosis. // American J Medicine, 2006 Vol. 21, pp. 1453-1460Emkey R.D., Ettinger M.: Improving compliance and persistence with bisphosphonate therapy for osteoporosis. // American J Medicine, 2006 Vol. 21, pp. 1453-1460Fleisch H.: The bisphosphonate ibandronate given daily as well as discontinuously, decreases bone resorption and increases calcium retention as assessed by 45Ca kinetics in the intact rat. // Osteoporosis International, 1996, Vol. 6, pp. 166-170Fleisch H.: The bisphosphonate ibandronate given daily as well as discontinuously, decreases bone resorption and increases calcium retention as assessed by 45Ca kinetics in the intact rat. // Osteoporosis International, 1996, Vol. 6, pp. 166-170Frost H.M.: Tetracycline based histological analysis of bone remodeling. // J. Calcified Tissue Research, 1969, Vol. 3, pp.211-237Frost H.M.: Tetracycline based histological analysis of bone remodeling. // J. Calcified Tissue Research, 1969, Vol. 3, pp.211-237Gamero P., Hausher E., Chapuy M.C., et.al.: Markers of bone resorption predict hip fracture in elderly women: the Epidos prospective study. J. Bone Mineral Research, 1996, Vol. 11, pp. 1531-1538Gamero P., Hausher E., Chapuy M.C., et.al.: Markers of bone resorption predict hip fracture in elderly women: the Epidos prospective study. J. Bone Mineral Research, 1996, Vol. 11, pp. 1531-1538Garnero P., Dargent-Molina P., Hans D., Schott A.M., Breart G., Meunier P.J., Delmas P.D. Do markers of bone resorption add to bone mineral density and ultrasonographic heel measurement for the predic tion of hip fracture in elderly women? The EPIDOS prospective study. J. Osteoporosis International, 1998, Vol. 8, pp. 563-569Garnero P., Dargent-Molina P., Hans D., Schott A.M., Breart G., Meunier P.J., Delmas P.D. Do markers of bone resorption add to bone mineral density and ultrasonographic heel measurement for the predic tion of hip fracture in elderly women? The EPIDOS prospective study. J. Osteoporosis International, 1998, Vol. 8, pp. 563-569Garnero P., Sornay-Rendu E., Claustrat B., Delmas P.D.: Bio chemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: the OFELY study. J. Bone Min eral Research, 2000 Vol. 15, pp. 1526-1536Garnero P., Sornay-Rendu E., Claustrat B., Delmas P.D.: Bio chemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: the OFELY study. J. Bone Min eral Research, 2000 Vol. 15, pp. 1526-1536Hamilton B., McCoy K., Taggert H.: Tolerability and compliance with residronate in clinical practice. // Osteoporosis International, 2003, Vol. 14, pp. 259-262Hamilton B., McCoy K., Taggert H.: Tolerability and compliance with residronate in clinical practice. // Osteoporosis International, 2003, Vol. 14, pp. 259-262Harris S.T., Watts N.B., Genant H.K., et al.: Effects of risedro nate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. // J American Medical Association, 1999, Vol. 282 (14): 1344-1352 8Harris S.T., Watts N.B., Genant H.K., et al.: Effects of risedro nate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. // J American Medical Association, 1999, Vol. 282 (14): 1344-1352 8Herrmann Z., Schoeter К.Н.: The new bisphosphonate ibandro nate in the treatment of tumor-induced hypercalcemia. // Oncology, 1999, Vol. 22, pp. 208-211Herrmann Z., Schoeter К.Н.: The new bisphosphonate ibandro nate in the treatment of tumor-induced hypercalcemia. // Oncology, 1999, Vol. 22, pp. 208-211Hochberg M.C., Greenspan S., Wasnich R.D., Miller P., Thompson D.E., Ross P.D.: Changes in bone density and turnover explain the reduc tions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents. // J. Clinical Endocrinology Metabolism, 2002, Vol. 87, pp. 1586-1592Hochberg M.C., Greenspan S., Wasnich R.D., Miller P., Thompson D.E., Ross P.D.: Changes in bone density and turnover explain the reduc tions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents. // J. Clinical Endocrinology Metabolism, 2002, Vol. 87, pp. 1586-1592Johnel O.: The socioeconomic burden of fractures: today and in the 21st century. // American J Medicine, 1997, Vol. 103, 20S-26SJohnel O.: The socioeconomic burden of fractures: today and in the 21st century. // American J Medicine, 1997, Vol. 103, 20S-26SKaram S.M.: Lineage commitment and maturation of epithelial cells in the gut. // Frontiers Bioscience, 1999, Vol. 4, D286-D298Karam S.M.: Lineage commitment and maturation of epithelial cells in the gut. // Frontiers Bioscience, 1999, Vol. 4, D286-D298Lalla S., Hothorn L.A., Haag N., Bader R., Bauss F.: Lifelong administration of high doses of ibandronate increases bone mass and maintains bone quality of lumbar vertebrae in rats. // J. Osteoporosis International, 1998, Vol. 8, pp. 97-103 28. 28 № 2/2006 Остеопороз и остеопатии ОБЗОРЫLalla S., Hothorn L.A., Haag N., Bader R., Bauss F.: Lifelong administration of high doses of ibandronate increases bone mass and maintains bone quality of lumbar vertebrae in rats. // J. Osteoporosis International, 1998, Vol. 8, pp. 97-103 28. 28 № 2/2006 Остеопороз и остеопатии ОБЗОРЫLeu С., Rodan G.A., Reszka A.A.: Relative binding affinities of bisphosphonates for human bone (abstract). // J. Bone Mineral Research, 2003, Vol. 18, (suppl 2) S374Leu С., Rodan G.A., Reszka A.A.: Relative binding affinities of bisphosphonates for human bone (abstract). // J. Bone Mineral Research, 2003, Vol. 18, (suppl 2) S374Liberman U.A., Weiss S.R., Broil J., et al.: Effect of oral alen dronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. // New England J Medicine, 1995, Vol. 333 (22), pp. 1437-1443 4Liberman U.A., Weiss S.R., Broil J., et al.: Effect of oral alen dronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. // New England J Medicine, 1995, Vol. 333 (22), pp. 1437-1443 4McClung M.R., Geusens P., Miller P.D., et al.: Effect of risedronate on risk of hip fracture in elderly women. Hip Intervention Program Study Group. // New England J Medicine, 2001, Vol. 344, pp. 333-340 10McClung M.R., Geusens P., Miller P.D., et al.: Effect of risedronate on risk of hip fracture in elderly women. Hip Intervention Program Study Group. // New England J Medicine, 2001, Vol. 344, pp. 333-340 10Monier-Faugere M.C., Friedler R.M., Bauss F., Malluche H.H.: A new bisphosphonate, BM 21.0955 prevents bone loss associated with cessation of ovarian function in experimental dogs. // J. Bone Mineral Research, 1993, Vol. 8, pp. 1345-1355Monier-Faugere M.C., Friedler R.M., Bauss F., Malluche H.H.: A new bisphosphonate, BM 21.0955 prevents bone loss associated with cessation of ovarian function in experimental dogs. // J. Bone Mineral Research, 1993, Vol. 8, pp. 1345-1355Monier-Faugere M.C., Geng Z., Paschalis E.P., Qi Q., Arnala I., Bauss F., Boskey A.L., Malluche H.H.: Intermittent and continuous admin istration of the bisphosphonate ibandronate in ovariohysterectomized beagle dogs: effects on bone morphometry and mineral properties. // J. Bone Mineral Research, 1999, Vol. 14, pp. 1768-1778Monier-Faugere M.C., Geng Z., Paschalis E.P., Qi Q., Arnala I., Bauss F., Boskey A.L., Malluche H.H.: Intermittent and continuous admin istration of the bisphosphonate ibandronate in ovariohysterectomized beagle dogs: effects on bone morphometry and mineral properties. // J. Bone Mineral Research, 1999, Vol. 14, pp. 1768-1778Muller R., Hannan M.K., Smith S.Y., Bauss F. Intermittent iban dronate preserves bone quality and bone strength and quality in ovari ectomized cynomolgus monkeys. // J. Bone Mineral Research, 2006 (in press)Muller R., Hannan M.K., Smith S.Y., Bauss F. Intermittent iban dronate preserves bone quality and bone strength and quality in ovari ectomized cynomolgus monkeys. // J. Bone Mineral Research, 2006 (in press)Peter C.P., Handt L.K., Smith S.M.: Esophageal irritation due to alendronate sodium tablets: possible mechanisms. // Digestive Disease Sciences, 1998, Vol. 43, pp. 1998-2002Peter C.P., Handt L.K., Smith S.M.: Esophageal irritation due to alendronate sodium tablets: possible mechanisms. // Digestive Disease Sciences, 1998, Vol. 43, pp. 1998-2002Pols H.A., Felsenberg D., Hanley D.A., et al.: Multinational, pla cebo-controlled randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Fosamax International Trial Study Group. // Osteoporosis International, 1999, Vol. 9, pp. 461-468 7Pols H.A., Felsenberg D., Hanley D.A., et al.: Multinational, pla cebo-controlled randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Fosamax International Trial Study Group. // Osteoporosis International, 1999, Vol. 9, pp. 461-468 7Ralston S.H., Thiebaud D., Herrmann Z., et al.: Dose-response study of ibandronate in the treatment of cancer-associated hypercalce mia. // British J Cancer, 1997, Vol. 75, pp. 295-300Ralston S.H., Thiebaud D., Herrmann Z., et al.: Dose-response study of ibandronate in the treatment of cancer-associated hypercalce mia. // British J Cancer, 1997, Vol. 75, pp. 295-300Recker R.R., Gallagher R., Amonkar M., Smith J.C., MacCosbe P.E.: Medication persistence is better with weekly bisphosphonates, but it remains suboptimal (abstract SA407). J Bone Mineral Research, 2004, Vol. 19(Suppl l). S172Recker R.R., Gallagher R., Amonkar M., Smith J.C., MacCosbe P.E.: Medication persistence is better with weekly bisphosphonates, but it remains suboptimal (abstract SA407). J Bone Mineral Research, 2004, Vol. 19(Suppl l). S172Recker R.R., Weinsten R.S., Chesnut C.H., Schimmer R.C., Mahoney P., Hughes C., Bonvoisin B., Meunier P.J.: Histomorphometric evaluation of daily and intermittent oral ibandronate in women with postmenopausal osteoporosis: results from the BONE study. // Osteoporosis International, 2004, Vol. 15, pp. 231-237Recker R.R., Weinsten R.S., Chesnut C.H., Schimmer R.C., Mahoney P., Hughes C., Bonvoisin B., Meunier P.J.: Histomorphometric evaluation of daily and intermittent oral ibandronate in women with postmenopausal osteoporosis: results from the BONE study. // Osteoporosis International, 2004, Vol. 15, pp. 231-237Reginster J., Felsenberg D., Cooper C., Stakkestad J.A., Miller P.D., Kendler D.L., Adami S., McClung M.R., Bolognese M.A., Civitelli R.,Dumont E., Bonvoisin B., Recker R.R., Delmas P.D.: A new concept for bisphosphonate therapy: a rationale for the development of monthly oral dosing of ibandronate. // Osteoporosis International, 2006, Vol. 17, pp. 159-166Reginster J., Felsenberg D., Cooper C., Stakkestad J.A., Miller P.D., Kendler D.L., Adami S., McClung M.R., Bolognese M.A., Civitelli R.,Dumont E., Bonvoisin B., Recker R.R., Delmas P.D.: A new concept for bisphosphonate therapy: a rationale for the development of monthly oral dosing of ibandronate. // Osteoporosis International, 2006, Vol. 17, pp. 159-166Reginster J., Minne H.W., Sorensen O.H., et al.: Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. // Osteoporosis International, 2000 Vol. 11, pp. 83-91 9Reginster J., Minne H.W., Sorensen O.H., et al.: Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. // Osteoporosis International, 2000 Vol. 11, pp. 83-91 9Reginster J.Y., Adami S., Lakatos P., et al.: Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2- year results from the MOBILE study. // J. Annals Rheumatic Disease, 2006, Vol. 65, pp. 654-661 2Reginster J.Y., Adami S., Lakatos P., et al.: Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2- year results from the MOBILE study. // J. Annals Rheumatic Disease, 2006, Vol. 65, pp. 654-661 2Reginster J.Y., Christiansen C., Roux C., Fechtenbaum J., Rouillon A., Tou K.P.: Intermittent cyclic tiludronate in the treatment of osteoporosis. // Osteoporosis International, 2001, Vol. 12, pp. 169-177Reginster J.Y., Christiansen C., Roux C., Fechtenbaum J., Rouillon A., Tou K.P.: Intermittent cyclic tiludronate in the treatment of osteoporosis. // Osteoporosis International, 2001, Vol. 12, pp. 169-177Reid I.R., Brown J.P., Burckhardt P., et al.: Intravenous zoledronic acid in postmenopausal women with low bone mineral density. // New England J Medicine, 2002, Vol. 346, pp. 653-661Reid I.R., Brown J.P., Burckhardt P., et al.: Intravenous zoledronic acid in postmenopausal women with low bone mineral density. // New England J Medicine, 2002, Vol. 346, pp. 653-661Rizzoli R., Greenspan S.L., Bone G., Schnitzer T.J., for the Alendronate once-weekly study group: Two-year results of once-weekly administration of alendronate 70mg for the treatment of postmenopausal osteoporosis. // J Bone Mineral Research, 2002, Vol. 17, pp. 1988- 1996Rizzoli R., Greenspan S.L., Bone G., Schnitzer T.J., for the Alendronate once-weekly study group: Two-year results of once-weekly administration of alendronate 70mg for the treatment of postmenopausal osteoporosis. // J Bone Mineral Research, 2002, Vol. 17, pp. 1988- 1996Rosen C.J.: Postmenopausal osteoporosis. // New England J Medicine, 2005, Vol. 353, pp. 595-603Rosen C.J.: Postmenopausal osteoporosis. // New England J Medicine, 2005, Vol. 353, pp. 595-603Ryan P.J., Blake G.M., Davie M., Haddaway M., Gibson T., Fogelman I.: Intermittent oral disodium pamidronate in established osteoporosis: a 2 year double-masked placebo-controlled study of efficacy and safety. // Osteoporosis International, 2000, Vol. 11, pp. 171-176Ryan P.J., Blake G.M., Davie M., Haddaway M., Gibson T., Fogelman I.: Intermittent oral disodium pamidronate in established osteoporosis: a 2 year double-masked placebo-controlled study of efficacy and safety. // Osteoporosis International, 2000, Vol. 11, pp. 171-176Sambrook P., Olszynski W.P., Leigh C., Masanauskaite D., Bon voisin B., Emkey R.: Similar safety profile of intravenous ibandronate injection and daily oral ibandronate in postmenopausal osteoporosis: the DIVA study. // Arthritis Rheumaism, 2005, Vol. 52 (suppl 9), S296Sambrook P., Olszynski W.P., Leigh C., Masanauskaite D., Bon voisin B., Emkey R.: Similar safety profile of intravenous ibandronate injection and daily oral ibandronate in postmenopausal osteoporosis: the DIVA study. // Arthritis Rheumaism, 2005, Vol. 52 (suppl 9), S296Schnitzer T., Bone H.G., Crepaldi G., Adami S., McClung M., Kiel D., Felsenberg D., Recker R.R., Tonino R.P., Roux C., Pinchera A., Foldes A.J., Greenspan S.L., Levine M.A., Emkey R., Santora A.C., Kaur A.., Thompson D.E., Yates J., Orloff J.J.: Therapeutic equivalence of alendronate 70mg once-weekly and alendronate 10 mg daily in the treatment of osteopo rosis. Alendronate Once-Weekly Study Group. // Aging (Milano), 2000, Vol. 12, pp. 1-12Schnitzer T., Bone H.G., Crepaldi G., Adami S., McClung M., Kiel D., Felsenberg D., Recker R.R., Tonino R.P., Roux C., Pinchera A., Foldes A.J., Greenspan S.L., Levine M.A., Emkey R., Santora A.C., Kaur A.., Thompson D.E., Yates J., Orloff J.J.: Therapeutic equivalence of alendronate 70mg once-weekly and alendronate 10 mg daily in the treatment of osteopo rosis. Alendronate Once-Weekly Study Group. // Aging (Milano), 2000, Vol. 12, pp. 1-12Sernbo I., Johnell O.: Consequences of a hip fracture: a prospective study over a 1 year. // Osteoporosis International, 1993, Vol. 3, pp. 148-153; Beatriz J.E., Perry H.M.: Age-related osteoporosis, Clinical Geriatric Medicine, 1994, Vol. 10, pp. 575-577Sernbo I., Johnell O.: Consequences of a hip fracture: a prospective study over a 1 year. // Osteoporosis International, 1993, Vol. 3, pp. 148-153; Beatriz J.E., Perry H.M.: Age-related osteoporosis, Clinical Geriatric Medicine, 1994, Vol. 10, pp. 575-577Smith S.Y., Recker R.R., Hannan M., Muller R., Bauss E.: Intermittent intravenous administration of the bisphosphonate ibandronate prevents bone loss and maintains bone strength and quality in ovariectomized cynomolgus monkeys. // J. Bone, 2003, Vol. 32, pp. 45-55Smith S.Y., Recker R.R., Hannan M., Muller R., Bauss E.: Intermittent intravenous administration of the bisphosphonate ibandronate prevents bone loss and maintains bone strength and quality in ovariectomized cynomolgus monkeys. // J. Bone, 2003, Vol. 32, pp. 45-55Tosteoson A.N., Grove M.R., Hammond C.S., Moncur M.M., Ray G.T., Hebert G.M., Pressman A.R., Ettinger В.: Early discontinuation of treatment for osteoporosis. // American J. Medicine, 2003, Vol. 115, pp. 209-216Tosteoson A.N., Grove M.R., Hammond C.S., Moncur M.M., Ray G.T., Hebert G.M., Pressman A.R., Ettinger В.: Early discontinuation of treatment for osteoporosis. // American J. Medicine, 2003, Vol. 115, pp. 209-216Tripathy D., Budde M., Bergstorm В.: Oral daily ibandronate: an effective and convenient therapy for the reduction of skeletal complications in breast cancer patients with bone metastases (Bondronat MF4434 Study Group). // Annual Oncology, 2002, Vol. 13 (suppl 5) p. 168 (Abstact)Tripathy D., Budde M., Bergstorm В.: Oral daily ibandronate: an effective and convenient therapy for the reduction of skeletal complications in breast cancer patients with bone metastases (Bondronat MF4434 Study Group). // Annual Oncology, 2002, Vol. 13 (suppl 5) p. 168 (Abstact)Wasnich R.D., Miller P.D.: Antifracture efficacy of antiresorptive agents are related to changes in bone density. // J. Clinical Endocrinology Metabolism, 2000, Vol. 85, pp. 231-236Wasnich R.D., Miller P.D.: Antifracture efficacy of antiresorptive agents are related to changes in bone density. // J. Clinical Endocrinology Metabolism, 2000, Vol. 85, pp. 231-236Watts N.B., Harris S.T., Genant H.K., et al.: Intermitten cyclical etidronate treatment of postmenopausal osteoporosis. // New England J Medicine, 1990, Vol. 323, pp. 73-79Watts N.B., Harris S.T., Genant H.K., et al.: Intermitten cyclical etidronate treatment of postmenopausal osteoporosis. // New England J Medicine, 1990, Vol. 323, pp. 73-79Weel A.E.A.M., Seibel M.J., Hofman A., et.al.: Which fractures are associated with high bone resorption in elderly women? The Rotterdam study. J. Bone Mineral Research, 1999, Vol. 14, S160 World Health Organization Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Technical Report Series, 1994, № 843, WHO, Geneva World Health Organization Guidelines for the preclinical evaluation and clinical trials in osteoporosis. WHO, GenevaWeel A.E.A.M., Seibel M.J., Hofman A., et.al.: Which fractures are associated with high bone resorption in elderly women? The Rotterdam study. J. Bone Mineral Research, 1999, Vol. 14, S160 World Health Organization Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Technical Report Series, 1994, № 843, WHO, Geneva World Health Organization Guidelines for the preclinical evaluation and clinical trials in osteoporosis. WHO, GenevaКлинические рекомендации Остеопороз: диагностика, профилактика и лечение (под редакцией проф. Л.И. Беневоленской и проф. О.М. Лесняк). Геотар-Медиа, Москва. 2005: 171стр.Клинические рекомендации Остеопороз: диагностика, профилактика и лечение (под редакцией проф. Л.И. Беневоленской и проф. О.М. Лесняк). Геотар-Медиа, Москва. 2005: 171стр.
The authors declare that there are no conflicts of interest present.